AbbVie Immunology Deal History & Licensing Activity
AbbVie Immunology is a large pharma headquartered in US. Over the past three years, AbbVie Immunology has been involved in 8 licensing and acquisition transactions, with a primary focus on Other (6 deals).
Deals (12mo)
4
Active Trials
35
Top Modality
Other
Focus Area
Dermatology
AbbVie Immunology Recent Deal Activity
Licensing, acquisition, and partnership transactions involving AbbVie Immunology in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| BI 655066 | AbbVie | Other | Phase 3 | license | Mar 2026 |
| BI 655064 | AbbVie | Other | Phase 1 | license | Mar 2026 |
| CLD-423 (IL-23p19/TL1A bispecific) | AbbVie | Bispecific Antibodies | Phase 1 | collaboration | Jun 2025 |
AbbVie Immunology Pipeline Focus
Therapeutic areas and modalities where AbbVie Immunology is most active based on deal history and clinical trial data.
Therapeutic Areas
AbbVie Immunology Strategic Signals
Key indicators of AbbVie Immunology's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches AbbVie Immunology's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Dermatology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Dermatology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for dermatology
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
About AbbVie Immunology Licensing & Deal Activity
AbbVie Immunology is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 8 deals over the past three years, AbbVie Immunology ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for AbbVie Immunology include Dermatology (4 deals and trials), Gastroenterology (2 deals and trials), Neurology (1 deal and trial), and Ophthalmology (1 deal and trial). In terms of modality, AbbVie Immunology has shown particular interest in other, bispecific antibodies, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for AbbVie Immunology and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against AbbVie Immunology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.